Work

P19.01 RATIONALE-303 Phase 3 Tislelizumab vs Docetaxel in Previously Treated Advanced NSCLC: China Subgroup Analysis

Year: 2021

Type: conference-abstract

Source: Journal of Thoracic Oncology

DOI: 10.1016/j.jtho.2021.08.351

Authors: Y. Fan, D. Huang, Z. Ma, X. Yu, Y. Cheng, Y. Ma, Y. Wang, Z. Pan, C. Yu, C. Zhou

Institutions: Zhejiang Cancer Hospital, University of Chinese Academy of Sciences, Tianjin Medical University Cancer Institute and Hospital, Zhengzhou University, Henan Cancer Hospital, Jilin Province Tumor Hospital, BeiGene (China), Tongji University, Shanghai Pulmonary Hospital

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W3206232489

Cites:

Cited by:

Related to: 10